QUEBEC CITY, June 3, 2013 /PRNewswire/ - DiagnoCure Inc. (TSX:
CUR)
(OTCQX: DGCRF) (the "Corporation") today reported financial and
operational results for the second quarter ended April 30, 2013. The
Corporation announced a net loss of $849,344 or $0.02
per share for
this quarter. At the end of the quarter, cash and short-term
investments stood at $4,849,305.
Second Quarter Highlights
On April 2, 2013, the Corporation
initiated trading on OTCQX International under the symbol "DGCRF".
OTCQX is the best U.S. OTC
marketplace, providing an opportunity to significantly broaden
and
enhance DiagnoCure's access to and exposure within the U.S.
financial
markets. In addition, the Corporation's information has been
made
available via Standard & Poor's Corporation Records
Listing Program.
Because the concept that PCA3 can become a product of reference to
help
better diagnose prostate cancer patients is becoming more and
more
evident in the clinical community, we are in the midst of a
productive
dialogue with Hologic's management regarding ways to optimize the
value
of PCA3 for both companies.
Despite the current unsettled status of molecular diagnostics
reimbursement policy in the U. S., PROGENSA® PCA3 royalties
from U.S.
sales paid to DiagnoCure in the second quarter by
Hologic Gen-Probe
increased 21% compared with second quarter results in fiscal year
2012.
This increase represents the fifth straight quarter over
quarter
increase in the U.S. market-associated-PROGENSA® PCA3 second
quarters
royalties received by DiagnoCure since 2008.
On April 29, 2013, during the Annual
and Special Meeting of
Shareholders, Dr. Yves Fradet,
President and Chief Medical Officer
announced the initiation of a search for a full-time CEO to
achieve
maximum leverage from DiagnoCure's product development platform.
The
new CEO will be expected to lead and enhance DiagnoCure's business
and
product development efforts.
Results of the Second Quarter 2013
Total revenues for the second quarter 2013 were $164,262 compared with
$1,063,131 for the same period of
2012. This decrease of $898,869
is
attributable to the payment made by Gen-Probe in relation to the
FDA
milestone reached for PROGENSA® PCA3 in the second quarter 2012
($502,600). The remaining decrease is
attributable to the termination,
on January 11, 2013 of the
development and license agreements signed in
June 2011 with Signal Genetics. That
development agreement provided
$387,266 of revenues in the second
quarter 2012. In the second quarter
2013, royalty revenues from Hologic Gen-Probe decreased by
$4,401, or
2.6%, to $164,262, from $168,663 for the same period of 2012. This
decrease is attributable to a decrease of 39% in the European
market,
reflecting a general softness in the European markets offset by
an
increase of 21% in the U.S. market reflecting primarily an increase
in
the average selling price of PROGENSA® PCA3. This increase was
offset
partially by changes in the reimbursement environment for
molecular
diagnostic tests.
Operating expenses decreased by $321,741, to $1,013,606 for the second
quarter of 2013 from $1,335,347 for
the same period of 2012. This
decrease was mainly attributable to the termination of the
development
agreement performed in Q2 2012 in support to the
PrevistageTM GCC Colorectal Cancer Staging Test.
Financial Data
|
For the three months periods ended
April 30
|
2013
|
2012
|
|
$
|
$
|
Research collaboration revenues
|
—
|
387,266
|
License and royalty revenues
|
164,262
|
675,865
|
Total revenues
|
164,262
|
1,063,131
|
Operating expenses (before stock-based compensation, depreciation
and
amortization)
|
774,042
|
1,052,250
|
Net profit (loss) (before stock-based compensation, depreciation
and
amortization)
|
(609,780)
|
10,881
|
Stock-based compensation
|
22,094
|
43,813
|
Depreciation of property, plant and equipment
|
17,865
|
31,691
|
Amortization of intangible asset
|
199,605
|
207,593
|
Net loss and comprehensive loss
|
(849,344)
|
(272,216)
|
Basic and diluted net loss per share
|
(0.02)
|
(0.01)
|
Weighted average number of common shares outstanding
|
43,040,471
|
43,033,471
|
Consolidated Balance Sheets
|
April 30, 2013
|
October 31, 2012
|
Cash, cash equivalents, temporary and long-term
investments
|
4,849,305
|
5,824,771
|
Total assets
|
9,673,265
|
11,256,369
|
Shareholders' equity
|
8,871,282
|
10,448,087
|
Number of shares outstanding
|
43,040,471
|
43,040,471
|
Conference call
DiagnoCure's management will host a conference call at 4:30 p.m. (EDT)
on June 3, 2013. Interested
participants may listen to the call by
dialing 1-888-231-8191 or 514-807-9895 and referencing code
77464078
approximately 15 minutes prior to the call. The Corporation will
also
provide a live webcast of the call. Interested participants may
access
the webcast on DiagnoCure's website at www.diagnocure.com, through
a link on the Investors page - Presentations. A replay of
the
webcast will be available on DiagnoCure's website for those unable
to
participate in the live webcast.
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation
that
develops and commercializes high-value cancer diagnostic tests
that
increase clinician and patient confidence in making critical
treatment
decisions. In 2008, the Corporation launched a colorectal
cancer
staging test through its U.S. CLIA laboratory. PrevistageTM GCC
is
currently available for licensing. The Corporation has granted
a
worldwide exclusive license to Gen-Probe, now a wholly-owned
subsidiary
of Hologic Inc. operating as Hologic Gen-Probe, for the development
and
commercialization of a prostate cancer test using PCA3,
DiagnoCure's
proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA®
PCA3
test is commercialized in Europe
under CE mark and is approved for
commercialization in Canada and
the United States. For more
information, please visit www.diagnocure.com.
Forward?looking statements
This release may contain forward?looking statements that involve
known
and unknown risks, uncertainties and assumptions that may cause
actual
results to differ materially from those expected.
Forward-looking
statements can be identified by the use of the conditional or
forward-looking terminology such as "anticipates", "assumes",
"believes", "estimates", "expects", "intend", "may", "plans",
"projects", "should", "will", or the negative thereof or other
variations thereon. Forward-looking statements also include any
other
statements that do not refer to historical facts. All such
forward-looking statements are made pursuant to the
"safe-harbour"
provisions of applicable Canadian securities laws. By their
very
nature, forward?looking statements are based on expectations
and
hypotheses and also involve risks and uncertainties, known and
unknown,
many of which are beyond DiagnoCure's control. Forward-looking
statements are presented for the purpose of assisting investors
and
others in understanding certain key elements of the
Corporation's
current objectives, strategic priorities, expectations and plans,
and
in obtaining a better understanding of the Corporation's business
and
anticipated operating environment. Readers are cautioned that
such
information may not be appropriate for other purposes and that
they
should not place undue reliance on these forward?looking
statements.
For instance, any forward-looking statements regarding the outcome
of
research and development projects, clinical studies and future
revenues, including those related to PROGENSA® PCA3, are based
on
management expectations and such outcome may vary materially
depending
on global political and economic conditions, dependence on
collaboration partners, uncertainty of healthcare reimbursement,
and
marketing and distribution challenges. In addition, the reader
is
referred to the applicable general risks and uncertainties
described in
DiagnoCure's most recent Annual Information Form under the
heading
"Risk Factors". DiagnoCure undertakes no obligation to publicly
update
or revise any forward?looking statements contained herein
unless
required by the applicable securities laws and regulations.
SOURCE DiagnoCure inc.